BRAF and thyroid cancer: Our findings align with prior research on different molecular alterations suggest that TERTp/BRAF V600E and TERTp/RAS molecular alterations may behave differently and should be studied separately in larger cohorts with greater statistical power to better understand their distinct impacts on thyroid cancer progression.